{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:02:21Z","timestamp":1778878941695,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Blood eosinophils are considered a biomarker for the treatment of chronic obstructive pulmonary disease (COPD). Population-based studies are needed to better understand the determinants of the blood eosinophil count (BEC) in individuals with and without COPD.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>EPISCAN II is a multicentre, cross-sectional, population-based epidemiological study aimed at investigating the prevalence and determinants of COPD in Spain. Study subjects were randomly selected from the general population, and COPD was defined by a post-bronchodilator FEV<jats:sub>1<\/jats:sub>\/FVC\u2009&lt;\u20090.7. For the pre-specified outcomes related to BEC, the first 35 COPD and 35 non-COPD subjects were consecutively recruited in 12 of the participating centres with the objective of analysing 400 individuals in each group. Baseline BEC and its association with demographic, clinical and functional variables were analysed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 326 COPD and 399 non-COPD subjects were included in the analysis. The mean age (standard deviation [SD]) was 63.2\u00a0years (11.0), 46.3% were male, and 27.6% were active smokers. BEC was significantly higher in individuals with COPD [192 cells\/\u03bcL (SD: 125) vs. 160 cells\/\u03bcL (SD: 114); p\u2009=\u20090.0003]. In a stepwise multivariate model, being male, active smoker and having a previous diagnosis of asthma were independently associated with having a higher BEC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This population-based study estimated the distribution of eosinophils in the healthy adult population and concluded that COPD patients have a significantly higher BEC. Male sex, active smoking and concomitant asthma were significantly associated with a higher BEC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-022-01965-3","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T12:03:00Z","timestamp":1646481780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Determinants of blood eosinophil levels in the general population and patients with COPD: a population-based, epidemiological study"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9850-9520","authenticated-orcid":false,"given":"Marc","family":"Miravitlles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Soler-Catalu\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan B.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Garc\u00eda-R\u00edo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"de Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Alfageme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciro","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Miguel","family":"Rodr\u00edguez Gonz\u00e1lez-Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Guadalupe","family":"S\u00e1nchez-Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Ancochea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borja G.","family":"Cos\u00edo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,5]]},"reference":[{"issue":"9","key":"1965_CR1","doi-asserted-by":"publisher","first-page":"e0160770","DOI":"10.1371\/journal.pone.0160770","volume":"11","author":"BG Cosio","year":"2016","unstructured":"Cosio BG, Soriano JB, L\u00f3pez-Campos JL, Calle M, Soler JJ, de Torres JP, et al. Distribution and outcomes of a phenotype-based Approach to guide COPD management: results from the CHAIN cohort. PLoS ONE. 2016;11(9):e0160770.","journal-title":"PLoS ONE"},{"key":"1965_CR2","first-page":"86","volume":"48","author":"M Miravitlles","year":"2012","unstructured":"Miravitlles M, Calle M, Soler-Catalu\u00f1a JJ. Clinical phenotypes of COPD. Identification, definition and implications for guidelines. Arch Bronconeumol. 2012;48:86\u201398.","journal-title":"Arch Bronconeumol"},{"issue":"6","key":"1965_CR3","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","volume":"141","author":"JH Yun","year":"2018","unstructured":"Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037\u201347.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1965_CR4","doi-asserted-by":"publisher","first-page":"00188","DOI":"10.1183\/23120541.00188-2020","volume":"6","author":"M Kerkhof","year":"2020","unstructured":"Kerkhof M, Chaudhry I, Pavord ID, Miravitlles M, Kook Rhee C, Halpin DMG, et al. Blood eosinophil count predicts treatment failure and hospital readmission for COPD. ERJ Open Res. 2020;6(4):00188\u20132020.","journal-title":"ERJ Open Res"},{"key":"1965_CR5","first-page":"13","volume":"57","author":"M Miravitlles","year":"2021","unstructured":"Miravitlles M, Monteagudo M, Solntseva I, Alc\u00e1zar B. Blood eosinophil counts and their variability and risk of exacerbations in COPD: a population-based study. Arch Bronconeumol. 2021;57:13\u201320.","journal-title":"Arch Bronconeumol"},{"issue":"2","key":"1965_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.arbres.2019.09.015","volume":"56","author":"R Golpe","year":"2020","unstructured":"Golpe R, Dacal D, Sanju\u00e1n-L\u00f3pez P, Mart\u00edn-Robles I, P\u00e9rez-de-Llano LA. Plasma eosinophil count and patient-centered events in chronic obstructive pulmonary disease in real-life clinical practice. Arch Bronconeumol. 2020;56(2):129\u201330.","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"1965_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12931-020-01482-1","volume":"21","author":"D Singh","year":"2020","unstructured":"Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, Magnussen H, et al. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res. 2020;21(1):240.","journal-title":"Respir Res"},{"issue":"5","key":"1965_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.arbres.2019.08.023","volume":"56","author":"JJ Soler-Catalu\u00f1a","year":"2020","unstructured":"Soler-Catalu\u00f1a JJ, Novella L, Soler C, Nieto ML, Esteban V, S\u00e1nchez-Toril F, et al. Clinical characteristics and risk of exacerbations associated with different diagnostic criteria of asthma-COPD overlap. Arch Bronconeumol. 2020;56(5):282\u201390.","journal-title":"Arch Bronconeumol"},{"key":"1965_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","volume":"71","author":"ID Pavord","year":"2016","unstructured":"Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid\/long-acting \u03b2-2 agonist efficacy in COPD. Thorax. 2016;71:118\u201325.","journal-title":"Thorax"},{"key":"1965_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.rmed.2018.03.016","volume":"138","author":"G Brusselle","year":"2018","unstructured":"Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, et al. Blood eosinophil levels as a biomarker in COPD. Respir Med. 2018;138:21\u201331.","journal-title":"Respir Med"},{"issue":"5","key":"1965_CR11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1164\/rccm.201912-2384PP","volume":"202","author":"D Singh","year":"2020","unstructured":"Singh D, Bafadhel M, Brightling CE, Sciurba FC, Curtis JL, Martinez FJ, et al. Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;202(5):660\u201371.","journal-title":"Am J Respir Crit Care Med"},{"key":"1965_CR12","unstructured":"Global Strategy For The Diagnosis, Management, And Prevention Of Chronic Obstructive Pulmonary Disease. 2021 Report. https:\/\/goldcopd.org\/wp-content\/uploads\/2020\/11\/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf [Accessed May 16th, 2021."},{"key":"1965_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.arbres.2021.03.005","volume":"58","author":"M Miravitlles","year":"2021","unstructured":"Miravitlles M, Calle M, Molina J, Almagro P, G\u00f3mez JT, Trigueros JA, et al. Spanish COPD Guidelines (GesEPOC) 2021: updated pharmacological treatment of stable COPD. Arch Bronconeumol 2022;58:69\u201381. https:\/\/doi.org\/10.1016\/j.arbres.2021.03.005.","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"1965_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12931-019-1130-y","volume":"20","author":"CF Vogelmeier","year":"2019","unstructured":"Vogelmeier CF, Kostikas K, Fang J, Tian H, Jones B, Morgan CL, et al. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respir Res. 2019;20(1):178.","journal-title":"Respir Res"},{"key":"1965_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/15412555.2018.1441275","volume":"15","author":"S Landis","year":"2018","unstructured":"Landis S, Suruki R, Maskell J, Bornar K, Hilton E, Compton C. Demographic and clinical characteristics of COPD patients at different blood eosinophil levels in the UK clinical practice research datalink. COPD. 2018;15:177\u201384.","journal-title":"COPD"},{"issue":"2","key":"1965_CR16","doi-asserted-by":"publisher","first-page":"1800616","DOI":"10.1183\/13993003.00616-2018","volume":"52","author":"Y \u00c7olak","year":"2018","unstructured":"\u00c7olak Y, Afzal S, Nordestgaard BG, Marott JL, Lange P. Combined value of exhaled nitric oxide and blood eosinophils in chronic airway disease: the Copenhagen General Population Study. Eur Respir J. 2018;52(2):1800616.","journal-title":"Eur Respir J"},{"issue":"5","key":"1965_CR17","doi-asserted-by":"publisher","first-page":"1901874","DOI":"10.1183\/13993003.01874-2019","volume":"55","author":"S Hartl","year":"2020","unstructured":"Hartl S, Breyer MK, Burghuber OC, Ofenheimer A, Schrott A, Urban MH, et al. Blood eosinophil count in the general population: typical values and potential confounders. Eur Respir J. 2020;55(5):1901874.","journal-title":"Eur Respir J"},{"issue":"4","key":"1965_CR18","doi-asserted-by":"publisher","first-page":"1900633","DOI":"10.1183\/13993003.00633-2019","volume":"54","author":"U Kolsum","year":"2019","unstructured":"Kolsum U, Southworth T, Jackson N, Singh D. Blood eosinophil counts in COPD patients compared to controls. Eur Respir J. 2019;54(4):1900633.","journal-title":"Eur Respir J"},{"key":"1965_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.arbres.2018.05.011","volume":"55","author":"I Alfageme","year":"2019","unstructured":"Alfageme I, de Lucas P, Ancochea J, Miravitlles M, Soler-Catalu\u00f1a JJ, Garc\u00eda-R\u00edo F, et al. 10 Years After EPISCAN: a new study on the prevalence of COPD in Spain\u2014a summary of the EPISCAN II protocol. Arch Bronconeumol. 2019;55:38\u201347.","journal-title":"Arch Bronconeumol"},{"key":"1965_CR20","first-page":"61","volume":"57","author":"JB Soriano","year":"2021","unstructured":"Soriano JB, Alfageme I, Miravitlles M, de Lucas P, Soler-Catalu\u00f1a JJ, Garc\u00eda-R\u00edo F, et al. Prevalence and Determinants of COPD in Spain: EPISCAN II. Arch Bronconeumol. 2021;57:61\u20139.","journal-title":"Arch Bronconeumol"},{"key":"1965_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","volume":"26","author":"MR Miller","year":"2005","unstructured":"Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS\/ERS Task Force. Standardization of spirometry. Eur Respir J. 2005;26:319\u201338.","journal-title":"Eur Respir J"},{"key":"1965_CR22","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, ERS Global Lung Function Initiative, et al. Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324\u201343.","journal-title":"Eur Respir J"},{"key":"1965_CR23","first-page":"479","volume":"41","author":"S De Abajo","year":"2001","unstructured":"De Abajo S, Larriba R, M\u00e1rquez S. Validity and reliability of the Yale Physical Activity Survey in Spanish elderly. J Sports Med Phys Fitness. 2001;41:479\u201385.","journal-title":"J Sports Med Phys Fitness"},{"key":"1965_CR24","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.arbres.2011.07.002","volume":"47","author":"D Donaire-Gonz\u00e1lez","year":"2011","unstructured":"Donaire-Gonz\u00e1lez D, Gimeno-Santos E, Serra I, Roca J, Balcells E, Rodr\u00edguez E, et al. Validaci\u00f3n del cuestionario de actividad f\u00edsica de Yale en pacientes con enfermedad pulmonar obstructiva cr\u00f3nica. Arch Bronconeumol. 2011;47:552\u201360.","journal-title":"Arch Bronconeumol"},{"key":"1965_CR25","doi-asserted-by":"crossref","unstructured":"American Thoracic Society ATS Statement: Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med 2002; 166: 111\u2013117.","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"1965_CR26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1183\/09031936.05.00034905","volume":"26","author":"N MacIntyre","year":"2005","unstructured":"MacIntyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720\u201335.","journal-title":"Eur Respir J"},{"key":"1965_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.acra.2012.11.010","volume":"20","author":"AM Owrangi","year":"2013","unstructured":"Owrangi AM, Etemad-Rezai R, McCormack DG, Cunningham IA, Parraga G. Computed tomography density histogram analysis to evaluate pulmonary emphysema in ex-smokers. Acad Radiol. 2013;20:537\u201345.","journal-title":"Acad Radiol"},{"key":"1965_CR28","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1038\/nm.2971","volume":"18","author":"C Galban","year":"2012","unstructured":"Galban C, Han M, Boes J, Chughtai K, Meyer C, Johnson T, et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med. 2012;18:1711\u20135.","journal-title":"Nat Med"},{"key":"1965_CR29","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.ejrad.2016.09.010","volume":"85","author":"A Nambu","year":"2016","unstructured":"Nambu A, Zach J, Schroeder J, Jin G, Kim SS, Kim YI, et al. Quantitative computed tomography measurements to evaluate airway disease in chronic obstructive pulmonary disease: relationship to physiological measurements, clinical index and visual assessment of airway disease. Eur J Radiol. 2016;85:2144\u201351.","journal-title":"Eur J Radiol"},{"issue":"9","key":"1965_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(17)30217-5","volume":"5","author":"M Bafadhel","year":"2017","unstructured":"Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? Lancet Respir Med. 2017;5(9):747\u201359.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1965_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1378\/chest.15-1055","volume":"149","author":"BG Cosio","year":"2016","unstructured":"Cosio BG, Soriano JB, L\u00f3pez-Campos JL, Calle-Rubio M, Soler-Cataluna JJ, de Torres JP, et al. Defining the asthma-COPD overlap syndrome in a COPD cohort. Chest. 2016;149(1):45\u201352.","journal-title":"Chest"},{"key":"1965_CR32","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/15412555.2017.1386644","volume":"14","author":"AI Papaioannou","year":"2017","unstructured":"Papaioannou AI, Kostikas K, Papaporfyriou A, Angelakis L, Papathanasiou E, Hillas G, et al. Emphysematous phenotype is characterized by low blood eosinophils: a cross-sectional study. COPD. 2017;14:635\u201340.","journal-title":"COPD"},{"issue":"5","key":"1965_CR33","doi-asserted-by":"publisher","first-page":"2000838","DOI":"10.1183\/13993003.00838-2020","volume":"57","author":"WC Tan","year":"2021","unstructured":"Tan WC, Bourbeau J, Nadeau G, Wang W, Barnes N, Landis SH, et al. High eosinophil counts predict decline in FEV1: results from the CanCOLD study. Eur Respir J. 2021;57(5):2000838.","journal-title":"Eur Respir J"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-01965-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-01965-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-01965-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T12:16:10Z","timestamp":1646482570000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-01965-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,5]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1965"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-01965-3","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,5]]},"assertion":[{"value":"1 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committees of each of the participating centres, and all participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Marc Miravitlles has received speaker or consulting fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Laboratorios Esteve, Gebro Pharma, Kamada, GlaxoSmithKline, Grifols, Menarini, Mereo Biopharma, Novartis, pH Pharma, Palobiofarma SL, Rovi, TEVA, Spin Therapeutics, Verona Pharma and Zambon, and research grants from Grifols. Juan Jos\u00e9 Soler-Catalu\u00f1a has received speaker fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, GlaxoSmithKline, Menarini, Novartis and Teva, and and consulting fees from AstraZeneca, Bial, Boehringer Ingelheim, GlaxoSmithKline, Ferrer and Novartis. Francisco Garc\u00eda-R\u00edo has received speaker or consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, Pfizer and Rovi, and research grants from Chiesi, Esteve, Gebro Pharma, GlaxoSmithKline, Menarini and TEVA. Julio Ancochea has received speaker or consulting fees from Actelion, Air Liquide, Almirall, AstraZeneca, Boehringer Ingelheim, Carburos M\u00e9dica, Chiesi, Faes Farma, Ferrer, GlaxoSmithKline, InterMune, Linde Healthcare, Menarini, MSD, Mundipharma, Novartis, Pfizer, Roche, Rovi, Sandoz, Takeda y Teva. Inmaculada Alfageme has no conflicto of interest. Ciro Casanova has received speaker or consulting fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, and research grants from GlaxoSmithKline, Menarini and AstraZeneca. M. Guadalupe S\u00e1nches-Herrero is a GSK employee within the Medical Department. Borja G Cosio has received speaker or consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, Sanofi, TEVA, and research grants from Menarini, AstraZeneca and Boehringer-Ingelheim.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}